The effects of 2% rebamipide ophthalmic solution on the tear functions and ocular surface of the superoxide dismutase-1 (sod1) knockout mice

Investigative Ophthalmology and Visual Science

Volumn 54, Issue 12, 2013, Pages 7793-7802

  Ohguchi, Takeshi ^a   Kojima, Takashi ^b   Ibrahim, Osama M ^b   Nagata, Taeko ^b   Shimizu, Takahiko ^c   Shirasawa, Takuji ^d   Kawakita, Tetsuya ^b   Satake, Yoshiyuki ^e   Tsubota, Kazuo ^b   Shimazaki, Jun ^e   Ishida, Susumu ^a  

^a HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c CHIBA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^d JUNTENDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^e TOKYO DENTAL COLLEGE   (Japan)

Author keywords

Dry eyes; Inflammation; Secretagogue

Indexed keywords

4 HYDROXYNONENAL; 8 HYDROXYDEOXYGUANOSINE; COPPER ZINC SUPEROXIDE DISMUTASE; FLUORESCEIN; GAMMA INTERFERON; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; INTERLEUKIN 17; INTERLEUKIN 6; INTERLEUKIN 7; MUCIN 1; MUCIN 4; MUCIN 5AC; OCULAR ANTIINFLAMMATORY AGENT; REBAMIPIDE; ROSE BENGAL; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL TISSUE; ARTICLE; CELL DENSITY; CONJUNCTIVA; CONJUNCTIVA EPITHELIUM; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; EYE INJURY; FLOW CYTOMETRY; GENE EXPRESSION; GOBLET CELL; IMMUNOHISTOCHEMISTRY; LACRIMATION; MALE; MOUSE; NONHUMAN; OCULAR SURFACE DISEASE; OXIDATIVE STRESS; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; TEAR FILM;

DRY EYES; INFLAMMATION; SECRETAGOGUE;

ALANINE; ANIMALS; CONJUNCTIVA; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRY EYE SYNDROMES; ENZYME INHIBITORS; MALE; MICE; MICE, KNOCKOUT; OPHTHALMIC SOLUTIONS; QUINOLONES; SUPEROXIDE DISMUTASE; TEARS;

EID: 84888083474     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.13-13128     Document Type: Article

References (43)

1. Lemp MA. The definition and classification of dry eye disease: report of the Definition And Classification Subcommittee of the International Dry Eye Work Shop. Ocul Surf. 2007;5:75-92.
2. Dogru M, Matsumoto Y, Tsubota K. The role of oxidative stress and inflammation in the pathogenesis of dry eye. Inflamm Regen. 2007;27:559-564.
3. Schaumberg DA, Sullivan DA, Buring JE, Dana MR. Prevalence of dry eye syndrome among US women. Am J Ophthalmol. 2003;136:318-326.
4. Schein OD, Hochberg MC, Munoz B, et al. Dry eye and dry mouth in the elderly: a population-based assessment. Arch Intern Med. 1999;159:1359-1363.
5. Schein OD, Munoz B, Tielsch JM, et al. Prevalence of dry eye among the elderly. Am J Ophthalmol. 1997;124:723-728.
6. Munoz B, West SK, Rubin GS, et al. Causes of blindness and visual impairment in a population of older Americans: The Salisbury Eye Evaluation Study. Arch Ophthalmol. 2000;118:819-825.
7. Moss SE, Klein R, Klein BE. Prevalence of and risk factors for dry eye syndrome. Arch Ophthalmol. 2000;118:1264-1268.
8. Christen WG, Manson JE, Glynn RJ, et al. Low-dose aspirin and risk of cataract and subtypes in a randomized trial of US physicians. Ophthalmic Epidemiol. 1998;5:133-142.
9. Christen WG, Gaziano JM, Hennekens CH. Design of Physicians Health Study II. A randomized trial of beta-carotene, vitamins E and C, and multivitamins, in prevention of cancer, cardiovascular disease, and eye disease, and review of results of completed trials. Ann Epidemiol. 2000;10:125-134.
10. Chia EM, Mitchell P, Rochtchina E, et al. Prevalence and associations of dry eye syndrome in an older population: the Blue Mountains Eye Study. Clin Experiment Ophthalmol. 2003;31:229-232.
11. McCarty CA, Bansal AK, Livingston PM, et al. The epidemiology of dry eye in Melbourne, Australia. Ophthalmology. 1998;105:1114-1119.
12. Lin PY, Tsai SY, Cheng CY, et al. Prevalence of dry eye among an elderly Chinese population in Taiwan: the Shihpai Eye Study. Ophthalmology. 2003;110:1096-1101.
13. Lee AJ, Lee J, Saw SM, et al. Prevalence and risk factors associated with dry eye symptoms: a population based study in Indonesia. Br J Ophthalmol. 2002;86:1347-1351.
14. Pflugfelder S, Geerling G, Kinoshita S, et al. Management and therapy of dry eye disease. report of the Management and Therapy Subcommittee of the International Dry EyeWorkshop (2007). Ocul Surf. 2007;5:163-178.
15. Arakawa T, Higuchi K, Fujiwara Y, et al. 15th anniversary of rebamipide: looking ahead to the new mechanisms and new applications. Dig Dis Sci. 2005;50:S3-S11.
16. Watanabe S, Wang XE, Hirose M, Osada T, Tanaka H, Sato N. Rebamipide prevented delay of wound repair induced by hydrogen peroxide and suppressed apoptosis of gastric epithelial cells in vitro. Dig Dis Sci. 1998;43:S107-S112.
17. Watanabe T, Higuchi, K, Taira K, et al. Rebamipide reduces delay in gastric ulcer healing in cyclooxygenase-2-deficient mice. Dig Dis Sci. 2005;50:S63-S69.
18. Naito Y, Yoshikawa T, Tanigawa T, et al. Hydroxyl radical scavenging by rebamipide and related compounds: electron paramagnetic resonance study. Free Radic Biol Med. 1995;18:117-123.
19. Naito Y, Yoshikawa T, Yoshida N, Kondo M. Role of oxygen radical and lipid peroxidation in indomethacin-induced gastric mucosal injury. Dig Dis Sci. 1995;43:S30-S34.
20. Kurokawa T, Joh T, Ikai M, Seno K, Yokoyama Y, Itoh M. Rebamipide protects against oxygen radical-mediated gastric mucosal injury in rats. Dig Dis Sci. 1998;43:S113-S117.
21. Sakurai K, Osaka T, Yamasaki K. Rebamipide reduces recurrence of experimental gastric ulcers: role of free radicals and neutrophils. Dig Dis Sci. 2005;50:S90-S96.
22. Ríos JD, Shatos MA, Urashima H, Dartt DA. Effect of OPC-12759 on EGF receptor activation, p44/p42 MAPK activity, and secretion in conjunctival goblet cells. Exp Eye Res. 2008;86:629-636.
23. Tanito M, Takahashi T, Kaidzu S, et al. Cytoprotective effects of rebamipide and carteolol hydrochloride against ultraviolet Binduced corneal damage in mice. Invest Ophthalmol Vis Sci. 2003;44:2980-2985.
24. Kojima T, Wakamatsu TH, Dogru M, et al. Age-related dysfunction of the lacrimal gland and oxidative stress. Am J Pathol. 2012;180:1879-1896.
25. Krabbe KS, Pedersen M, Bruunsgaard H. Inflammatory mediators in the elderly. Exp Gerontol. 2004;39:687-699.
26. Zoukhri D. Effect of inflammation on lacrimal gland function. Exp Eye Res. 2006;82:885-898.
27. Pflugfelder SC, Jones D, Ji Z, Afonso A, Monroy D. Altered cytokine balance in the tear fluid and conjunctiva of patients with Sjögren's syndrome keratoconjunctivitis sicca. Curr Eye Res. 1999;19:201-211.
28. Stern ME, Pflugfelder SC. Inflammation in dry eye. Ocul Surf. 2004;2:124-130.
29. Fox RI, Kang HI, Ando D, Abrams J, Pisa E. Cytokine mRNA expression in salivary gland biopsies of Sjögren's syndrome. J Immunol. 1994;152:5532-5539.
30. Narayanan S, Miller WL, McDermott AM. Conjunctival cytokine expression in symptomatic moderate dry eye subjects. Invest Ophthalmol Vis Sci. 2006;47:2445-2450.
31. Tishler M, Yaron I, Geyer O, Shirazi I, Naftaliev E, Yaron M. Elevated tear interleukin-6 levels in patients with Sjögren syndrome. Ophthalmology. 1998;105:2327-2329.
32. Bruunsgaard H, Pedersen BK. Age-related inflammatory cytokines and disease. Immunol Allergy Clin North Am. 2003;23:15-39.
33. De Paiva CS, Chotikavanich S, Pangelinan SB, et al. IL-17 disrupts corneal barrier following desiccating stress. Mucosal Immunol. 2009;2:243-253.
34. Zhang X, Chen W, De Paiva CS, et al. Interferon-γ exacerbates dry eye-induced apoptosis in conjunctiva through dual apoptotic pathways. Invest Ophthalmol Vis Sci. 2011;52:6279-6285.
35. Fujioka T, Arakawa T, Shimoyama T, et al. Effects of rebamipide, a gastro-protective drug on the Helicobacter pylori status and inflammation in the gastric mucosa of patients with gastric ulcer: a randomized double-blind placebo-controlled multicentre trial. Aliment Pharmacol Ther. 2003;18:146-152.
36. Kimura K, Morita Y, Orita T, Haruta J, Takeji Y, Sonoda KH. Protection of human corneal epithelial cells from TNF-αinduced disruption of barrier function by rebamipide. Invest Ophthalmol Vis Sci. 2013;17:2572-2760.
37. Pflugfelder SC, Corrales RM, de Paiva CS. T helper in dry eye disease [published online ahead of print September 4, 2013]. Exp Eye Res. doi:10.1016/j.exer.2013.08.013.
38. Zhenq X, de Paiva CS, Li DQ, Farley WJ, Pflugfelder SC. Desiccating stress promotion of Th17 differentiation by ocular surface tissues through a dendritic cell-mediated pathway. Invest Ophthalmol Vis Sci. 2010;51:3083-3091.
39. Kakeji Y, Urashima H, Aoki A, Shinohara H. Rebamipide increases the mucin-like glycoprotein production in corneal epithelial cells. J Ocular Pharmacol Ther. 2012;28:259-263.
40. Horikawa Y, Shatos MA, Hodges RR, et al. Activation of mitogen-activated protein kinase by cholinergic agonists and EGF in human compared with rat cultured conjunctival goblet cells. Invest Ophthalmol Vis Sci. 2003;44:2535-2544.
41. Kanno H, Horikawa Y, Hodges RR, et al. Cholinergic agonists transactivate EGFR and stimulate MAPK to induce goblet cell Secretion. Am J Physiol Cell Physiol. 2003;284:988.
42. Luttrell LM, Daaka Y, Lefkowitz RJ. Regulation of tyrosine kinase cascades by G-protein-coupled receptors. Curr Opin Cell Biol. 1999;11:177-183.
43. Sugden PH, Clerk A. Regulation of the ERK subgroup of MAP kinase cascades through G protein-coupled receptors. Cell Signal. 1997;9:337-351.